Xiaodi Tang | Cardiovascular Medicine | Best Researcher Award

Posted on 25/03/202525/03/2025 by Pencis

Dr. Xiaodi Tang | Cardiovascular Medicine | Best Researcher Award

Dr. Xiaodi Tang, Beijing Tsinghua Changgung Hospital, Tsinghua University, China

Dr. Xiaodi Tang is a Ph.D. candidate in Clinical Medicine at Tsinghua University, Beijing Tsinghua Changgung Hospital, specializing in heart rate variability (HRV) in heart failure. A licensed practicing physician in China, Dr. Tang completed residency training in cardiovascular medicine and holds a Master of Medicine from Harbin Medical University, focusing on SGLT2 inhibitors in HFpEF and diabetes. With expertise in advanced statistical analysis (R) and longitudinal cohort study design, Dr. Tang’s research aims to enhance cardiac risk assessment and personalized treatment strategies, contributing to precision medicine and innovative diagnostics in cardiovascular healthcare.

AUTHOR PROFILE

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Xiaodi Tang embarked on an academic journey rooted in medical excellence. Pursuing a Master of Medicine in Cardiovascular Internal Medicine at Harbin Medical University, Dr. Tang dedicated early research to the cardiovascular protection of sodium-glucose cotransporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction (HFpEF) and diabetes. This work laid the foundation for a deeper exploration into cardiovascular medicine, integrating clinical experience with scientific inquiry.

🏥PROFESSIONAL ENDEAVORS:

As a Licensed Practicing Physician in China, Dr. Tang has completed rigorous residency training in cardiovascular medicine, gaining hands-on experience in diagnosing and treating complex cardiac conditions. This clinical expertise has been instrumental in bridging the gap between research and patient care, ensuring that scientific advancements translate into improved treatment protocols.

🔍CONTRIBUTIONS AND RESEARCH FOCUS CARDIOVASCULAR MEDICINE:

Dr. Tang is currently a Ph.D. Candidate in Clinical Medicine at Tsinghua University, Beijing Tsinghua Changgung Hospital, with a research concentration on heart rate variability (HRV) in heart failure. By utilizing advanced statistical analysis (R) and longitudinal cohort study design, Dr. Tang’s research seeks to uncover new insights into cardiac autonomic regulation and its role in heart failure prognosis.

💉KEY RESEARCH CONTRIBUTIONS:

Heart Rate Variability (HRV) in Heart Failure – Investigating the predictive value of HRV for cardiovascular outcomes.
SGLT2 Inhibitors and Cardiovascular Protection – Exploring their therapeutic potential in HFpEF and diabetic patients.
Longitudinal Cohort Studies – Applying advanced methodologies to track cardiovascular health over time.

🌍IMPACT AND INFLUENCE:

Dr. Tang’s work holds significant implications for clinical cardiology, particularly in developing non-invasive biomarkers for heart failure prognosis. By integrating statistical modeling with clinical insights, this research has the potential to refine risk stratification and personalize treatment strategies for patients with cardiac disorders.

📚ACADEMIC CITES & RECOGNITION:

Dr. Tang’s contributions are gaining recognition in peer-reviewed journals and conferences, with citations expected to grow as research findings are published and disseminated within the global cardiology community. The emphasis on HRV as a diagnostic tool aligns with contemporary efforts to enhance precision medicine in cardiovascular care.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

With a strong foundation in cardiovascular medicine and clinical research, Dr. Tang is poised to make lasting contributions to the field. The future trajectory includes:
Furthering HRV-based diagnostics for cardiac conditions.
Developing innovative therapeutic approaches for heart failure patients.
Mentoring future researchers in cardiovascular studies.
Expanding clinical applications of AI-driven predictive analytics in cardiology.

Dr. Xiaodi Tang’s journey exemplifies a commitment to scientific advancement, clinical excellence, and transformative research in cardiovascular medicine. The integration of cutting-edge analytics, patient-centered studies, and innovative therapeutic exploration positions Dr. Tang as a rising leader in the global cardiology landscape.

💡CONCLUSION:

Dr. Xiaodi Tang’s dedication to cardiovascular research and clinical excellence is shaping the future of heart failure diagnostics and treatment. With a strong foundation in heart rate variability (HRV), SGLT2 inhibitors, and advanced statistical analysis, Dr. Tang is driving precision medicine forward. By integrating research, clinical expertise, and innovative methodologies, Dr. Tang’s work has the potential to redefine patient care and improve cardiovascular outcomes. As a rising leader in cardiology, Dr. Tang continues to push the boundaries of medical science, paving the way for more effective, personalized, and data-driven healthcare solutions.

TOP NOTABLE PUBLICATIONS:

“Association between ultra-short-term heart rate variability of time fluctuation and atrial fibrillation: evidence from MIMIC-IV”

Authors: Information not available in the provided sources.

Journal: Heart Rhythm O2

Year: 2025

“The association of triglyceride-glucose and triglyceride-glucose related indices with the risk of heart disease in a national”

Authors: Information not available in the provided sources.

Journal: Cardiovascular Diabetology

Year: 2025

QIU SUN | Vascular disease | Best Researcher Award

Posted on 04/03/202504/03/2025 by Pencis

Mr. QIU SUN | Vascular disease | Best Researcher Award

Mr. QIU SUN, Heilongjiang University of Chinese Medicine, China

Mr. Qiu Sun is the Director of the Department, Chief Physician, Associate Professor, and a Ph.D. candidate at Heilongjiang University of Chinese Medicine, China. A recognized expert in Traditional Chinese Medicine (TCM), he is a National Academic Successor and policy advisor in TCM healthcare. He has led multiple research projects, published SCI-indexed papers, and contributed to national textbooks. With two invention patents and numerous awards, he plays a key role in TCM education, clinical practice, and policy-making. His work focuses on integrative medicine, vascular diseases, and external treatments, making a significant impact on TCM’s modernization and global recognition.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Mr. Sun Qiu was born in June 1982 and pursued his medical education at Heilongjiang University of Chinese Medicine, graduating in June 2009. His academic journey in Traditional Chinese Medicine (TCM) was marked by dedication to both theoretical and clinical practice. Currently, he is a Ph.D. candidate, continuously expanding his expertise in integrative medicine while mentoring future medical professionals as a Master’s Supervisor.

🏥 PROFESSIONAL ENDEAVORS:

As the Director of the Department, Chief Physician, and Associate Professor, Sun Qiu plays a crucial role in shaping TCM medical practices. His extensive responsibilities include supervising medical teams, enhancing healthcare quality, and pioneering innovative treatment methodologies. His leadership has significantly contributed to policy development in TCM hospitals across Heilongjiang Province.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON VASCULAR DISEASE:

Mr. Sun Qiu has been actively involved in various high-impact research projects, including:

Principal Investigator for 1 provincial-level project, 3 department-level projects, and 2 university-level projects
Participant in a National Natural Science Foundation of China (NSFC) project
Published 2 SCI-indexed papers and over 20 other research papers
Editor, co-editor, or contributor to 8 published books, exceeding 700,000 words
Holds 2 invention patents, reflecting his innovative contributions to TCM

His research primarily focuses on integrated traditional Chinese and Western medicine surgery, vascular diseases, and external treatment techniques in TCM.

🌍 IMPACT AND INFLUENCE:

Mr. Sun Qiu’s influence extends beyond clinical practice into policy-making and education. His key roles include:

National Academic Successor of Key Clinical Specialties in TCM
Expert in the Traditional Chinese Medicine Policy Think Tank
National Expert for the Supervision of TCM Statistical Data Quality
Project Review Expert for Science and Technology Departments in Sichuan, Anhui, and Guangxi Provinces

His editorial contributions to the “14th Five-Year Plan” National Textbook showcase his commitment to shaping the future of TCM education.

📚 ACADEMIC CITES & JOURNAL CONTRIBUTIONS:

Mr. Sun Qiu is an esteemed peer reviewer for international and national journals, including:

Scientific Reports (UK)
BMC Gastroenterology
Clinical Epigenetics
Chinese Health Preservation
China Contemporary Medicine

His role as a reviewer ensures high-quality research in TCM and integrative medicine.

🏆 LEGACY AND FUTURE CONTRIBUTIONS:

Mr. Sun Qiu has received numerous prestigious awards, including:

Second Prize from the Heilongjiang Provincial Government
First Prize from the Heilongjiang Administration of Traditional Chinese Medicine
Advanced Individual of the National TCM Monitoring and Statistics Expert Advisory Committee
Outstanding Communist Party Member
Excellence in Teaching & Advanced Educator Awards

With his extensive contributions to TCM policy, research, and education, Sun Qiu’s legacy continues to inspire medical professionals. His future endeavors aim at advancing integrative medicine and fostering global collaboration in TCM research.

🌟 CONCLUSION:

Mr. Qiu Sun is a pioneering force in Traditional Chinese Medicine (TCM), blending innovation with time-honored medical wisdom. His contributions to research, education, and policy-making have significantly shaped the future of integrative medicine. With numerous awards, patents, and publications, he continues to inspire the next generation of TCM professionals. As a leader in clinical excellence and academic advancements, his work plays a vital role in modernizing TCM and expanding its global influence. His dedication ensures that Traditional Chinese Medicine thrives in the 21st century and beyond!

TOP NOTABLE PUBLICATION

The association between serum copper concentration and prevalence of diabetes among US adults with hypertension (NHANES 2011–2016)

Authors: Kaiming Wu, Lixia Chen, Yanyan Kong, Jian-Feng Zhuo, Sun Qiu, Jianfei Chang

Journal: Journal of Cellular and Molecular Medicine

Year: 2024

Dong MA | Cardiovascular Researches | Best Researcher Award

Posted on 04/03/202504/03/2025 by Pencis

Prof. Dong MA | Cardiovascular Researches | Best Researcher Award

Prof. Dong MA, Hebei Medical University, China

Prof. Dong Ma is a distinguished professor at Hebei Medical University, China, specializing in medical sciences and healthcare innovations. With a strong academic background, he has made significant contributions to biomedical research, clinical studies, and medical advancements. His work focuses on developing new treatments, improving patient care, and enhancing healthcare methodologies. Prof. Ma’s research is widely cited in prestigious medical journals, influencing global healthcare policies and practices. As a mentor and scholar, he continues to inspire future medical professionals while fostering international research collaborations. His dedication to medical excellence and innovation ensures a lasting impact in the field.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Prof. Dong Ma embarked on his academic journey with a strong foundation in medical sciences. He pursued his education in China, demonstrating exceptional aptitude in the field of medicine and research. His early academic years were marked by rigorous studies, participation in innovative projects, and a keen interest in medical advancements.

🏛️ PROFESSIONAL ENDEAVORS:

Prof. Ma is currently a distinguished professor at Hebei Medical University, China. Throughout his career, he has been actively involved in teaching, mentoring, and guiding students in medical sciences. His professional engagements extend beyond the classroom, contributing to the university’s research and global collaborations in medical research and healthcare advancements.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR RESEARCHES:

Prof. Ma’s research primarily revolves around medical sciences, healthcare innovations, and clinical applications. His work includes:

Biomedical Research: Investigating novel treatments and technologies in the medical field.
Clinical Studies: Conducting evidence-based research to improve patient care and treatment outcomes.
Medical Innovations: Developing and contributing to new methodologies and technologies in healthcare.

His dedication to research has significantly impacted both theoretical knowledge and practical medical applications, benefiting healthcare professionals and patients alike.

🌍 IMPACT AND INFLUENCE:

Prof. Ma’s contributions have made a profound impact on the medical community. His research has been cited extensively in academic journals, influencing policies and practices in the field of medicine. His work has also led to collaborations with international medical institutions, further amplifying his influence on global healthcare development.

📖 ACADEMIC CITATIONS:

Prof. Ma has been cited in numerous prestigious medical journals and research papers. His publications cover a wide range of topics, including:

Advances in medical treatments and techniques.
Healthcare policy improvements.
Breakthroughs in disease prevention and management.

His academic work serves as a valuable resource for researchers, scholars, and healthcare professionals worldwide.

🏅 LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Dong Ma’s legacy is built upon his relentless pursuit of medical excellence. His future contributions are expected to:

Drive Innovation: Further enhance medical technologies and treatment approaches.
Inspire Future Scholars: Mentor upcoming medical professionals and researchers.
Expand Global Collaborations: Strengthen research ties with international institutions for broader healthcare advancements.

🔥 CONCLUSION:

Prof. Dong Ma stands as a visionary leader in medical sciences, shaping the future of healthcare through groundbreaking research, innovation, and education. His dedication to improving patient care, advancing medical treatments, and mentoring future professionals has left a lasting impact on both academia and clinical practice. With numerous contributions to medical research and extensive collaborations worldwide, he continues to drive progress in healthcare. His legacy is defined by excellence, knowledge, and a passion for medical advancements, ensuring a brighter, healthier future for generations to come.

TOP NOTABLE PUBLICATIONS

The Impact of the Monocyte-to-High-Density Lipoprotein Cholesterol Ratio on the Prognosis of Patients with Non-Viral,Non-Alcoholic Hepatocellular Carcinoma:a Retrospective Cohort Study

Authors: Xianzhe Lou, Tongguo Miao, Shiya Zhang, Dong Ma, Yuemin Nan

Journal: Chinese General Practice

Year: 2025

Combined DeRitis ratio and alkaline phosphatase on the prediction of portal vein tumor thrombosis in patients with hepatocellular carcinoma

Authors: Tongguo Miao, Shiya Zhang, Yunjing Zhang, Dong Ma, Yuemin Nan

Journal: Scientific Reports

Year: 2024

Study on the relationship between Methylation of Neuregulin (NRG) Gene and Cervical Carcinoma

Authors: Xizhao Yan, Fenglan An, Zhenzhen Ding, Dong Ma, Xiaohui Yang

Journal: Pakistan Journal of Medical Sciences

Year: 2024

α-HBDH is a superior to LDH in predicting major adverse cardiovascular events in patients with acute aortic dissection

Authors: Yunjing Zhang, Yue Sun, Yongbo Zhao, Dong Ma

Journal: Heliyon

Year: 2024

Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease

Authors: Tongguo Miao, Xianzhe Lou, Shiming Dong, Dong Ma, Yuemin Nan

Journal: Journal of Hepatocellular Carcinoma

Year: 2024

Lingyan Chen | Cardiovascular Diseases | Best Researcher Award

Posted on 17/02/202517/02/2025 by Pencis

Dr. Lingyan Chen | Cardiovascular Diseases | Best Researcher Award

Dr. Lingyan Chen, Wenzhou Medical university, China

Dr. Lingyan Chen is an Associate Researcher at Wenzhou Medical University, China, specializing in mitochondrial quality control and disease pathogenesis. She holds a Ph.D. from Wenzhou Medical University (2019-2022) and completed a postdoctoral fellowship at Guangzhou Medical University (2019-2024). Her research focuses on gene knockout models, tumor studies, and cardiovascular pharmacology. She has received multiple awards, including honors from the Circulation Journal Awards (Japan) and the Zhejiang Society of Biochemistry. With extensive experience in molecular biology techniques, Dr. Chen continues to advance biomedical research, aiming to develop novel therapeutic strategies for metabolic and cardiovascular diseases.

AUTHOR PROFILE

Scopus Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Lingyan Chen embarked on her academic journey at Changsha Medical University, earning a B.Sc. degree (2006-2009). She then pursued a M.Sc. at The University of South China (USC) (2015-2018), where she focused on pathogenesis and prevention of atherosclerosis, supported by prestigious research grants. She completed her Ph.D. at Wenzhou Medical University (WMU) (2019-2022), concentrating on mitochondrial quality control and its implications for related diseases.

🏥PROFESSIONAL ENDEAVORS:

🔹 Guangzhou Medical University (Postdoctoral Researcher) (2019-2024) – Advanced research in mitochondrial pathogenesis and disease modeling.
🔹 Guangzhou Medical School (Assistant Professor) (2018) – Engaged in pharmacology research on cardiovascular diseases.
🔹 Guangzhou Medical University (Research Assistant) (2018) – Coordinated multi-institutional research projects and managed key laboratory operations.
🔹 The Second People’s Hospital of Changde (Pediatric Nurse) (2009-2015) – Provided clinical care for newborns and critically ill children, mentoring trainee nurses.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR DISEASES:

Dr. Chen’s research spans multiple domains in biomedical sciences, including:
✅ Mitochondrial Quality Control & Disease Mechanisms – Investigated gene knockout/knockin mice models, heterogeneous tumors, and disease modeling for liver cancer and diabetes.
✅ Cardiovascular Pharmacology – Conducted Western Blotting, qPCR, immunofluorescence, and genetic experiments on macrophage behavior.
✅ Atherosclerosis & Hypertriglyceridemia – Studied clinical patient data, serum sample analysis, and statistical evaluations to uncover disease mechanisms.

🌍IMPACT AND INFLUENCE:

Dr. Chen has significantly influenced mitochondrial pathogenesis and cardiovascular research, contributing valuable insights into gene expression, disease prevention, and targeted treatments. Her research findings have aided in therapeutic advancements, particularly in cardiovascular disorders and metabolic diseases.

📚ACADEMIC CITES & LEGACY:

Dr. Chen’s research has been published in top-tier scientific journals, earning citations in the fields of biochemistry, molecular biology, and cardiovascular medicine. Her work serves as a foundation for future studies in mitochondrial dysfunction and therapeutic innovations.

🚀FUTURE CONTRIBUTIONS & VISION:

As an Associate Researcher at Wenzhou Medical University (2025-Present), Dr. Chen continues her groundbreaking research in mitochondrial medicine and disease pathogenesis. She aims to:
🔹 Develop novel therapeutic strategies for cardiovascular and metabolic disorders.
🔹 Expand research on genetic and molecular mechanisms underlying disease progression.
🔹 Mentor the next generation of biomedical researchers and medical professionals.

🏆AWARDS AND HONORS:

🔹 2020 – Second Prize in the 16th Graduate Academic Competition, Wenzhou Medical University
🔹 2020 – Second Prize in the “Xinzhi” Youth Forum, Zhejiang Society of Biochemistry and Molecular Biology
🔹 2018 – Second Prize for Excellent Experimental Research Paper, Circulation Journal Awards (Japan)
🔹 2018 – Outstanding Communist of the University of South China
🔹 2017 – 3rd Prize, Young Investigator Oral Presentation, 14th National Conference on Atherosclerotic Diseases & China-Canada Symposium
🔹 2017 – Excellence Award, Young Investigator Oral Presentation, Cross-Strait Cardiovascular Science Symposium
🔹 2017 – 1st Scholarship, University of South China
🔹 2016 – 2nd Scholarship, University of South China
🔹 2015 – 2nd Scholarship, University of South China

🌟CONCLUSION:

Dr. Lingyan Chen’s dedication to biomedical research, particularly in mitochondrial quality control and cardiovascular pharmacology, has significantly contributed to understanding disease mechanisms and potential treatments. Her extensive experience in molecular biology, combined with numerous accolades and publications, underscores her impact in the scientific community. As she continues her research at Wenzhou Medical University, Dr. Chen remains committed to advancing medical science, mentoring future researchers, and developing innovative therapeutic strategies. Her work holds great promise for improving treatments for metabolic and cardiovascular diseases, making her a valuable figure in the field of biomedical research.

TOP NOTABLE PUBLICATIONS

Inhibition of mitochondrial OMA1 ameliorates osteosarcoma tumorigenesis

Authors: Chen, Lingyan; Chen, Dejian; Pan, Yiming; Zhang, Dawei; Xia, Xiaodan

Journal: Cell Death and Disease

Year: 2024

Ciclopirox drives growth arrest and autophagic cell death through STAT3 in gastric cancer cells

Authors: Chen, Lingyan; Chen, Dejian; Li, Jiwei; Lu, Xiaoang; Lu, Bin

Journal: Cell Death and Disease

Year: 2022

MicroRNA-377 inhibits atherosclerosis by regulating triglyceride metabolism through the DNA methyltransferase 1 in apolipoprotein E-knockout mice

Authors: Chen, Lingyan (First Author); Xia, Xiaodan; Zhao, Zhiwei; Gong, Dan; Ma, Xuefeng; Yu, Xuhui; Zhang, Qi; Wang, Shengqi; Dai, Xinyu; Zheng, Xianliang; Zhang, Dawei; Yin, Wende; Tang, ChaoKun

Journal: Circulation Journal

Year: 2018

Myocardin suppression increases lipid retention and atherosclerosis via downregulation of ABCA1 in vascular smooth muscle cells

Authors: Xia, Xiaodan; Yu, Xuhui; Chen, Lingyan (Co-first Author); Xie, Shuo; Feng, Yan; Yang, Rui; Zhao, Zhiwei; Li, Hui; Wang, Gang; Tang, ChaoKun

Journal: Biochimica et Biophysica Acta (BBA) – Molecular and Cell Biology of Lipids

Year: 2021

Heart shock protein 70 accelerates atherosclerosis by downregulating the expression of ABCA1 and ABCG1 through the JNK/Elk-1 pathway

Authors: Zhao, Zhiwei; Zhang, Min; Chen, Lingyan (Co-first Author); Gong, Dan; Xia, Xiaodan; Yu, Xuhui; Wang, Shengqi; Ou, Xue; Dai, Xinyu; Zheng, Xianliang; Zhang, Dawei; Tang, ChaoKun

Journal: Biochimica et Biophysica Acta

Year: 2018

Puerarin promotes ABCA1-mediated cholesterol efflux and decreases cellular lipid accumulation in THP-1 macrophages

Authors: Li, ChaoHui; Gong, Dan; Chen, Lingyan (Co-first Author); Zhang, Min; Xia, Xiaodan; Cheng, Hongping; Huang, Chen; Zhao, Zhiwei; Zheng, Xianliang; Tang, XueEr; Tang, ChaoKun

Journal: European Journal of Pharmacology

Year: 2017

IL-8 negatively regulates ABCA1 expression and cholesterol efflux via upregulating miR-183 in THP-1 macrophage-derived foam cells

Authors: Tang, XueEr; Li, Hui; Chen, Lingyan (Co-first Author); Xia, Xiaodan; Zhao, Zhiwei; Zheng, Xianliang; Zhao, GuoJun; Tang, ChaoKun

Journal: Cytokine

Year: 2019